A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
OBJECTIVE: This study aimed to describe real-world obesity medication (OM) prescribing and dispensing among adolescents and young adults (AYAs) and examine factors associated with dispensing. METHODS: A retrospective cohort linked Nemours Children's…
Background The rapid adoption of incretin-based therapies for obesity has raised questions regarding their comparative safety profiles. While the gynecological safety of glucagon-like peptide-1 (GLP-1) receptor agonists is documented, the potential r…
BACKGROUND AND STUDY AIMS: Comparison of the therapeutic effects of endoscopic botulinum toxin (BTX) injection and semaglutide (SME) injection in treatment of patients with obesity and weight regain after laparoscopic sleeve gastrectomy (LSG). PATIEN…
BACKGROUND/OBJECTIVE: Recent observational studies report conflicting evidence on whether semaglutide use is associated with non-arteritic anterior ischemic optic neuropathy (NAION). This systematic review synthesizes available evidence and criticall…
The intricate interplay of physiological, psychological, and social factors presents considerable challenges in addressing heart failure. It is imperative to comprehend the epidemiology and pathophysiology, identify predictors and their influence on…
Metabolic dysfunction-associated steatotic liver disease (MASLD), characterised by hepatic steatosis and metabolic dysfunction (i.e., obesity, type 2 diabetes, dyslipidaemia, and hypertension), is affecting over 30% of the adult population worldwide.…
BACKGROUND: Obesity-related heart failure with preserved ejection fraction (HFpEF) is associated with high morbidity and limited therapeutic options. Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like…
Obesity is currently considered as adiposity based chronic disease with BMI as therapeutic target for prevention of obesity associated complications. For treatment of obesity, a stepwise approach is recommended including multifactorial basal therapy…
AIM: We aimed to analyse trends and demographic and clinical profiles in initial prescriptions of semaglutide ("Ozempic") by general practitioners in New South Wales between 2020 and 2023. METHOD: This retrospective cohort study used electronic medic…
Pharmacotherapy is a key component of obesity management, yet treatment failure remains a prevalent challenge in clinical practice. Such failure may present as insufficient pharmacological response, early discontinuation, or post-treatment weight reg…
Lysosome-targeting chimeras (LYTAC) represent a revolutionary technology for targeted protein degradation. However, the scarcity of highly efficient lysosomal transport receptors poses a major bottleneck to LYTAC advancement. In previous studies, we…
Obesity and its sequelae cause significant morbidity and mortality worldwide. Current glucagon-like peptide-1 (GLP-1) receptor agonist-based treatments have significant side-effects associated with high rates of treatment discontinuation. Such concer…
AIM: This study used a network meta-analysis (NMA) as the primary approach to compare the efficacy and tolerability of GLP-1 receptor agonists and dual agonists in overweight or obese adults with and without Type 2 diabetes. MATERIALS AND METHODS: Pu…
CONTEXT: Recent studies suggest glucagon-like peptide receptor-1 agonists (GLP-1RA) and glucose-dependent insulinotropic polypeptide (GIP) may contribute to altered calcium metabolism. OBJECTIVE: This study examines the association between GLP-1RA/GI…
BACKGROUND: Chronic neuroinflammation is increasingly recognized not as a secondary effect but as a primary driver of neurodegenerative disease progression. In conditions such as Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis…
Räsänen and Ahola-Launonen recently offered a commentary on an ethical analysis I co-authored with Julian Savulescu on the use of semaglutide-based weight-loss drugs such as Ozempic. In this response, I continue the discussion by engaging their conce…
Semaglutide is a glucagon-like peptide 1 (GLP-1) agonist that has found widespread popularity as a weight loss product. Initially developed as a treatment for diabetes, the drug acts to stimulate the secretion of insulin, as well as suppress appetite…
Consumers precluded from obtaining semaglutide or tirzepatide by clinicians or insurers are turning to natural "GLP-1" transdermal patches. The Dietary Supplement Health and Education Act specifies dietary supplement products must be swallowed, so al…
AIMS: This systematic review and meta-analysis evaluated the long-term efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as adjunctive therapies for individuals with type 1 diabetes (T1D) and overweight or obesity. MATERIALS…